$GKOS

WEN LEANA sold $88K of GKOS

WEN LEANA sold 525 shares of GLAUKOS Corp (GKOS) at $167.63 on 2026-07-31.

Original reporting
SEC EDGAR · WEN LEANA
Published Aug 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest fact is the reported open-market sale size, price, and post-transaction holdings for a director. It does not include any operational or financial guidance changes.

02

Market read

Traders may note insider selling for sentiment monitoring, but the disclosed value (~$88K) is unlikely to be a standalone catalyst.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says none), but it also provides no context on total holdings, prior sales cadence, or reasons for the transaction.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-03, transaction dated 2026-07-31.

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp (GKOS).

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos director Wen Leana filed a Form 4 open-market sale of 525 shares at $167.63 on 2026-07-31, worth about $88K.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying corporate news, guidance, or operational catalyst in the text.

Market effects

No sector read-through is provided beyond a routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or planned liquidity needs and may not signal reduced confidence.

Key entities

  • GLAUKOS Corp

    Company whose director insider sale is disclosed via Form 4.

  • WEN LEANA

    Director reporting an open-market sale of 525 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.